Skip to main content
. 2013 Aug 13;109(5):1137–1146. doi: 10.1038/bjc.2013.463

Figure 6.

Figure 6

Specific blockade of the ERK pathway inhibits the invasiveness and metastasis of RCC cells. (A) The GRC-1 cells were pre-treated with U0126 and BI-D1870 (10 mM) for 1 h, and subsequently stimulated with fetal bovine serum (FBS) for 15 min. The blockade of RSK4 and ERK both lead to a decreased number of invasive and metastatic cells (*P<0.05 vs control). (B) Prior treatment of GRC-1 cells with U0126 abolished the activation of ERK1/2 and RSK4, whereas such treatment with the RSK inhibitor BI-D1870 almost completely suppressed RSK4 expression without affecting the activation of ERK1/2. Simutaneously, the expression of CD44 and MMP-9 were markedly reduced. β-Actin was showed as loading control (RSK4 antibody for immunoblot: JS-31, Santa Cruz Biotechnology).